Navigation Links
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV
Date:2/18/2011

>About Tibotec Pharmaceuticals Tibotec Pharmaceuticals is a global pharmaceutical and research development company. The Company's main research and development facilities are in Beerse, Belgium with offices in Titusville, NJ and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need. Tibotec Pharmaceuticals is a subsidiary of Johnson & Johnson.

Forward Looking StatementThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Tibotec and/or Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Neither Tibotec nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.Contacts: Media

Investor RelationsKa
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
6. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
7. Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS
8. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers
9. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
10. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
11. Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   , July 2, 2015 BGI ... Hong Kong has been accredited ... Kong facility is the first clinical next-generation-sequencing laboratory to ... , meeting the highest standard in clinical laboratory practices. Complementary ... 11 compliant laboratory process, and multiple ISO certifications, the ...
(Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
(Date:7/1/2015)... -- Eli Lilly and Company (NYSE: LLY ) will ... on Thursday, July 23, 2015. Lilly will also conduct a ... media to further detail the company,s financial performance. ... media and the general public can access a live webcast ... posted on Lilly,s website at www.lilly.com . A replay ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2
... Mylan Inc. (Nasdaq: MYL ) today ... entered into a settlement agreement with Warner Chilcott resolving ... as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 ... mg (28-Day Regimen). This medication is an oral contraceptive. ...
... NEW YORK, Oct. 19, 2011 Reportlinker.com announces ... in its catalogue: Syncria ... 2020 http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Forecasts to 2020 Summary ...
Cached Medicine Technology:Mylan Announces Femcon® Fe Settlement Agreement 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
(Date:7/2/2015)... , ... July 02, 2015 , ... After conducting a ... Yuma Regional Medical Center in Yuma, Ariz., has hired Robert Trenschel, DO, ... healthcare and medical management, Dr. Trenschel will assume his new duties at Yuma Regional ...
(Date:7/2/2015)... ... July 02, 2015 , ... The report ... Capsule manufacturers. The report is a valuable source of guidance and direction for ... and Chinese market for the Gelatin Capsule industry including capacity, production, production value, ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... is announcing with their launch an intention to partner with companies that share ... on the planet. Their innovative water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic ...
(Date:7/2/2015)... AL (PRWEB) , ... July 02, 2015 , ... Every year, DUI arrests and fatalities ... July may be the deadliest day of the year when it comes to being on ... “The National Highway Traffic Safety Association reports that 40% of all highway deaths between 2007 ...
(Date:7/2/2015)... ... 2015 , ... Today, East Liverpool City Hospital announced Pam Akin, RN, MSN, ... Hospital (ELCH). Pam is currently the Chief Nursing Officer at ELCH and will remain ... a master’s degree in health care administration as well as nursing. She has a ...
Breaking Medicine News(10 mins):Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:Attorney David Maloney Stresses Safety through Sobriety 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3
... Francisco Bay Area Affiliate of Susan G. Komen for the ... to applaud the introduction of the 21st Century Cancer ALERT ... Detection, R esearch and T reatment) Act, bipartisan ... and Kay Bailey Hutchison (R-TX). "It,s been more than ...
... from fertility clinic embryos that otherwise would be discarded ... to use U.S. funding for embryonic stem cell research ... would be discarded, the National Institutes of Health announced ... research -- such as using stem cells taken from ...
... April 17 Even though suicide outranks homicide as ... death certificates thwart healthcare policymakers who want to create ... a WVU study shows."The Institute of Medicine ... have been diagnosed with a mental disorder, but death ...
... United States Great Depression of 1929 has the American ... well-being across the parameters of occupational, spiritual, emotional, and ... people are at risk for suffering lowered self esteem, ... St. Thomas University Counseling Programs - initiated ...
... Penny Imaging Exchange has acquired new German technology to process the ... ... Bohemia, NY (Vocus) April 17, 2009 -- Penny Imaging ... the conversion of microfiche records to digital form - the ...
... (Nasdaq: SUAI ) ("SUA" or the ... leading independent proxy advisory firm, has recommended that stockholders vote ... nominees recommended by dissident stockholder Hallmark Financial Services, Inc. ("Hallmark"). ... 9:00 a.m. local time on May 5, 2009 at 222 ...
Cached Medicine News:Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 2Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 2Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 4Health News:Team Uncovers Discrepancy in Death Certificates Listing Suicide 2Health News:Good News for Tough Times: Small, Private University Responds to Today's Economic Challenges 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 2Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 3
... Digital Flexible Ureteroscope (DUR-D) incorporates many ... proven durable, market leading DUR® series ... first device utilizing Gyrus ACMIs proprietary, ... Metal Oxide Semi-Conductor (CMOS) distal sensor ...
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Inquire...
... elegant and sophisticated woman, the ... ophthalmic and sunwear styles. Frames ... of shapes and colors, designed ... and complexions. Many styles feature ...
Medicine Products: